Entropy Technologies LP Takes Position in Stryker Corporation $SYK

Entropy Technologies LP bought a new position in Stryker Corporation (NYSE:SYK) during the second quarter, according to its most recent filing with the SEC. The firm bought 5,467 shares of the medical technology company’s stock, valued at approximately $2,163,000.

Several other hedge funds have also bought and sold shares of SYK. Vanguard Group Inc. lifted its stake in shares of Stryker by 1.3% in the second quarter. Vanguard Group Inc. now owns 33,500,571 shares of the medical technology company’s stock valued at $13,253,831,000 after buying an additional 440,607 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in Stryker by 9.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock valued at $4,515,847,000 after acquiring an additional 1,021,496 shares in the last quarter. Geode Capital Management LLC boosted its stake in Stryker by 1.1% during the 2nd quarter. Geode Capital Management LLC now owns 7,393,611 shares of the medical technology company’s stock valued at $2,910,445,000 after purchasing an additional 79,654 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in Stryker by 13.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company’s stock worth $838,640,000 after purchasing an additional 261,058 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Stryker by 4.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,086,960 shares of the medical technology company’s stock worth $776,871,000 after purchasing an additional 83,954 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a research report on Saturday, October 18th. Truist Financial raised their price objective on Stryker from $392.00 to $400.00 and gave the company a “hold” rating in a research note on Friday, November 14th. Sanford C. Bernstein reiterated an “outperform” rating on shares of Stryker in a research note on Monday, November 3rd. BTIG Research reissued a “buy” rating and set a $410.00 price target on shares of Stryker in a research report on Friday, November 14th. Finally, Rothschild & Co Redburn started coverage on shares of Stryker in a research report on Thursday, September 18th. They issued a “neutral” rating and a $420.00 price objective for the company. Thirteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $434.37.

Stryker Stock Performance

NYSE SYK opened at $368.35 on Friday. The company has a market capitalization of $140.87 billion, a PE ratio of 48.79, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. Stryker Corporation has a 52-week low of $329.16 and a 52-week high of $406.19. The company has a 50-day simple moving average of $369.38 and a 200 day simple moving average of $380.68.

Stryker (NYSE:SYK) last released its earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, beating analysts’ consensus estimates of $3.13 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. During the same period in the prior year, the firm earned $2.87 EPS. The company’s revenue was up 10.2% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. On average, research analysts predict that Stryker Corporation will post 13.47 EPS for the current year.

Insider Transactions at Stryker

In other Stryker news, CAO William E. Berry, Jr. sold 1,953 shares of the company’s stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $365.49, for a total transaction of $713,801.97. Following the sale, the chief accounting officer directly owned 2,833 shares of the company’s stock, valued at $1,035,433.17. This represents a 40.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Ronda E. Stryker sold 276,173 shares of the stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the transaction, the director owned 2,702,108 shares of the company’s stock, valued at $954,600,714.24. This represents a 9.27% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 522,618 shares of company stock valued at $185,577,237. Corporate insiders own 5.90% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.